Vaginal Pessary Versus Expectant Management for Placenta Previa

Placenta Previa Clinical Trial

Official title:

Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01996345
• Other study ID #: OBX0028
• Status: Terminated
• Phase: N/A
• Start date: October 2016
• Est. completion date: September 5, 2018

Study information

• Verified date: September 2018
• Source: Mednax Center for Research, Education, Quality and Safety
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to perform a large multi-center randomized trial comparing the role of vaginal pessary versus expectant management in women with placenta previa between 22w0d and 32w0d of gestation in prolonging gestation until ≥36 weeks. Secondary outcomes will assess duration of antepartum admission, total blood loss, gestational age at delivery, type of cesarean delivery, and a composite neonatal outcome. The hypothesis is that the use of a vaginal pessary in patients presenting with placenta previa between 22-32 weeks will decrease delivery prior to 36 weeks as compared to expectantly managing these patients.

Description:

While the use of pessary in this scenario has not been previously assessed, it is reasonable to infer, from the data for use of pessary to prevent preterm birth, and the data regarding the efficacy of cervical cerclage in reducing bleeding and preterm birth in patients with placenta previa to this clinical conundrum. If cerclage improves pregnancy outcomes in patients with placenta previa, the use of a vaginal pessary should be a less-invasive but similarly efficacious alternative to maintain cervical length. The purpose of this study is to compare two treatment options reasonably used in clinical practice. Use of cervical pessary is not expected to increase antenatal costs beyond the minimal cost of the pessary. Additionally, given the results of the available clinical trials on cerclage maintaining cervical length and decreasing bleeding, this procedure has the potential to decrease the cost of both antepartum admissions for bleeding and neonatal care.

A substantial number of women with placenta previa will not hemorrhage until they reach the third trimester, thus, by allowing for enrollment and pessary placement as late as 32w0d, the intervention may be applied to the broadest "at risk" population. As previously mentioned literature on the use of cerclage in patients with placenta previa and short cervix are limited by a reduced number of eligible subjects and concern over safety issues has not been assuaged by these small studies. As pessary placement appears to carry little if any risk based on a number of published studies, eligibility can be expanded to any cervical length.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 17
• Est. completion date: September 5, 2018
• Est. primary completion date: September 5, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 54 Years

Eligibility

Inclusion Criteria:

• Participant age 18 years or older

• Gestational age between 22w0d and 32w0d, inclusive, at time of enrollment

• Singleton pregnancy

• Complete Placenta Previa

• Intact Membranes

• No allergies to material in pessary

• Plan to deliver at PI's hospital

• Informed consent obtained, signed/dated

Exclusion Criteria:

• Active preterm labor

• Nonreassuring fetal heart rate tracing

• Intrauterine fetal death

• Active bleeding (may be enrolled if hemostatic >48 hours)

• Ruptured membranes

• Any fetal condition likely to cause serious neonatal morbidity independent of gestational age: Fetal malformation likely to require surgery, Fetal malformation involving vital organs, Fetal viral infection, Hydrops fetalis,

• Known Uterine Anomaly

• Cervical Cerclage present at time of enrollment

• Maternal condition that warrant continued hospitalization (example severe preeclampsia, Diabetes out of control, maternal heart disease)

Related Conditions & MeSH terms

• Placenta Previa

Intervention

Procedure:
• Cervical Pessary Placement
For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.

Locations

Country	Name	City	State
United States	Denver Health and Hospital Authority	Denver	Colorado
United States	Presbyterian/St Luke's Hospital	Denver	Colorado
United States	Baylor/Texas Children's Hospital & Pavilion	Houston	Texas
United States	Long Beach Memorial Medical Center	Long Beach	California
United States	Norton Kosair Children's Hospital	Louisville	Kentucky
United States	Tulane - Lakeside Hospital for Women and Children	Metairie	Louisiana
United States	University of South Alabama Medical Center	Mobile	Alabama
United States	Touro Infirmary	New Orleans	Louisiana
United States	Good Samaritan Hospital	San Jose	California
United States	Swedish Medical Center	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Mednax Center for Research, Education, Quality and Safety	Obstetrix Medical Group

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Decrease Delivery Prior to 36 weeks in patients with a gestational age of 22.0- 32.0 presenting with placenta previa.	This outcome, a decrease in the number of delivery that occur before 36 weeks of pregnancy who have a diagnosed placenta previa. The gestational age is noted at the time of birth.	day of birth
Secondary	Need for packed red blood cells or hematologic product replacement	note the number of blood transfusions the baby received from birth until 60 days post birth	from birth to 60 days
Secondary	Neonate or Fetal Death	death of fetus or newborn up to 60 days post delivery	From time of trial entry to 60 days post birth (approximately 34 weeks)
Secondary	Neonatal Outcomes	Including birthweight, neonatal death, composite neonatal morbidity (any of the following: respiratory distress syndrome, bronchopulmonary dysplasia, severe intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis, or perinatal death.) and specific neonatal morbidities including: Apgar <3 at 5 min, ICU admission, , cord pH, 7.1.	From Birth to 60 days of Age
Secondary	Any adverse reactions to the cervical pessary.	unexpected adverse reaction such as cervical trauma, infection, allergy	from 0 to as many as 18 weeks.

External Links

•   Sponsors Website